ArticleBMC cancer2025
Identification and validation of key biomarkers for chemoresistance in oral squamous cell carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cisplatin resistance in oral squamous cell carcinoma: mechanisms, reversal strategies, and emerging technologies.Frontiers in physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aimed to elucidate the molecular mechanisms underlying cisplatin resistance in oral squamous cell carcinoma (OSCC) and to identify prognostic biomarkers that can guide personalized treatment strategies.
methodsDifferentially expressed genes (DEGs) between cisplatin-sensitive and resistant OSCC cells were identified using transcriptomic data from the GSE197561 dataset. Functional enrichment analyses were conducted to explore involved pathways. Weighted Gene Co-expression Network Analysis (WGCNA) and random survival forest algorithms were employed to identify key resistance-related gene modules and hub genes. Clinical relevance was validated using The Cancer Genome Atlas (TCGA) dataset, while immune cell profiling and functional validation in SCC9/CAL27 cisplatin-resistant models were conducted to elucidate biological significance.
resultsDEGs were significantly enriched in processes such as oxidative stress response, cell cycle regulation, and immune-inflammatory pathways. WGCNA and survival analysis identified a chemotherapy resistance-associated gene module and 10 core genes, including DUSP3 and SACM1L, whose high expression was correlated with poorer overall survival. A nomogram integrating TNM stage, age, and DUSP3 expression demonstrated superior predictive performance for patient prognosis. In analyses stratified by chemotherapy resistance, upregulated DUSP3 expression appeared to synergistically cooperate with malignant tumor progression. Immune profiling revealed reduced NK cell activity and decreased populations of resting CD4⁺ memory T cells in the resistant phenotype. Functional assays confirmed that cisplatin-resistant SCC9 and CAL27 cells exhibited accelerated proliferation and epithelial-mesenchymal transition (EMT), characterized by downregulated E-cadherin and upregulated N-cadherin and Vimentin. Notably, knockdown of DUSP3 significantly reversed these resistant phenotypes.
conclusionThis study provides a comprehensive multi-omics-based framework for understanding cisplatin resistance in OSCC. DUSP3 was identified as a key prognostic indicator, and the proposed nomogram may enhance precision oncology efforts for cisplatin-resistant OSCC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.